Market Overview
The
global Dravet syndrome market is expected to magnify its valuation at 8.5% CAGR
from 2017 to 2023 (forecast period). The increase noticed in the health
expenditure for research and development (R&D) and development of new
therapies are primary factors expected to drive the market growth. Other major
drivers include reimbursement policies offering coverage of rare diseases,
improvement in regulatory framework, and unmet medical needs of patients.
Adverse
effects of the drugs, low awareness of the disease, and low planning of
healthcare in low and mid income countries are some of the restraints which can
impede market growth.
Dravet
syndrome is a rare epileptic disorder affecting infants. The patient has
seizures which are triggered by hot temperatures or fevers. It is also known as
severe myoclonic epilepsy of infancy (SMEI). According to the National Center
for Advancing Sciences, nearly 15-25% of the cases of the disorder have a
family history of febrile seizures or epilepsy. The global Dravet syndrome
market report by Market Research Future (MRFR) has been compiled by a blend of
primary and secondary research.
Segmentation
The
global Dravet syndrome market is segmented on the basis of the type of
seizures, diagnosis, treatment & management, and end-user.
On
the basis of the type of seizures, it is classified as myoclonic seizures,
atonic seizures, partial seizures, absence seizures, tonic clonic seizures,
photosensitive seizures, and others.
On
the basis of the diagnosis, it is segmented as magnetic resonance imaging
(MRI), electroencephalography (EEG), SCN1A testing, and others.
On
the basis of the treatment & management, the market is segmented into
seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others.
The seizure medications segment is further classified into clobazam, stiripentol,
sodium valproate, and others.
On
the basis of the end-user, the global Dravet syndrome market is segmented into
pharmaceutical companies, hospitals, diagnostic laboratories, academic and
research institutes, and others.
No comments:
Post a Comment